Morgan Stanley interprets Vertex Pharmaceuticals Incorporated's (VRTX.US) billion-dollar acquisition of Crinetics: Filling gaps in endocrine pipeline layout, two core drugs open growth opportunities.

Morgan Stanley released a research report interpreting the $10 billion acquisition of Crinetics by Vertex Pharmaceuticals Incorporated (VRTX.US). This acquisition will add a fifth pillar of business for Vertex Pharmaceuticals Incorporated - endocrine drugs, filling in the company's pipeline layout. According to the announcement, the acquisition price of $85 per share represents a 102% premium over Crinetics' closing price on Monday. Vertex Pharmaceuticals Incorporated stated in a press release that, excluding the cash acquired in the transaction, the valuation of Crinetics is $8.8 billion, and it will boost the adjusted operating income in 2029. This is the largest deal in Vertex Pharmaceuticals Incorporated's history. The transaction is expected to be completed in the third quarter of 2026. The Morgan Stanley team predicts that Crinetics' revenue in 2027 and 2030 will be $183 million and $830 million, respectively, accounting for approximately 1% and 4% of Vertex Pharmaceuticals Incorporated's total revenue. Breakdown of the core pipeline assets of the acquisition Morgan Stanley points out that Crinetics has two key assets for rare endocrine diseases: the newly launched oral treatment for acromegaly, Palsonify; and the oral antagonist of the adrenocorticotropic hormone (ACTH) receptor, Atumelnant, which is in Phase 3 clinical trials for Congenital Adrenal Hyperplasia (CAH) and Phase 2 clinical trials for adrenocorticotropic hormone-dependent Cushing's Syndrome (ADCS). Adding to Vertex Pharmaceuticals Incorporated's internally developed type 1 diabetes stem cell drug, zimislecel, creates a complete matrix of rare endocrine pipelines. Vertex Pharmaceuticals Incorporated states that the total sales of Crinetics' key drugs are expected to exceed $5 billion, with Palsonify contributing to revenue growth immediately after the acquisition. Atumelnant alone for CAH is expected to generate billions of dollars, with additional performance growth potential in the ADCS area. The Morgan Stanley team predicts that by 2035, the sales of Palsonify for acromegaly indications will reach $1 billion after risk adjustment. Morgan Stanley believes that acromegaly belongs to orphan drug indications, so Palsonify may be exempt from US tariff-related regulations announced in April 2026. Palsonify is also conducting Phase 3 clinical trials for pseudohypoparathyroidism indications, but this is not the focus of this acquisition deal. The Morgan Stanley team also predicts that the peak sales of Atumelnant for CAH indications after risk adjustment will be approximately $500 million. In terms of ADCS indications, there are over 10,000 patients in the United States and about 15,000 patients overseas. It is worth noting that Morgan Stanley is serving as a financial advisor to Vertex Pharmaceuticals Incorporated, assisting the company in reaching the agreement to acquire Crinetics.